PT-141 gets called “the libido peptide.” Unlike most peptides sold online, it is also an FDA-approved drug. Under the name Vyleesi, bremelanotide is approved for low sexual desire in premenopausal women. The approval came with real trial data, and that data tells a more modest story than the marketing does.
Solid but modest for its approved use. Two large randomized trials in women showed a small but real improvement in desire and a drop in distress about low desire. They did not show more satisfying sexual experiences. In men, there are small Phase 2 studies for erectile dysfunction, but it was never approved for men.
Bremelanotide is a small ring-shaped peptide of seven amino acids. It is a close chemical cousin of Melanotan II, the tanning peptide, differing at just one end of the molecule. Both mimic a natural hormone called alpha-MSH. You may read that PT-141 is a “metabolite” of Melanotan II. That is not established. “Close analog” is accurate.
Palatin Technologies first developed it as a nasal spray for erectile dysfunction. Blood pressure spikes became a concern, and in 2008 Palatin stopped the program. It was reformulated as an injection under the skin and redirected toward women. The FDA approved Vyleesi in June 2019 for acquired, generalized hypoactive sexual desire disorder, or HSDD, in premenopausal women. Palatin sold Vyleesi to Cosette Pharmaceuticals around the start of 2024.
It activates melanocortin receptors, mainly MC4R in the brain and MC1R on pigment cells. It works on desire pathways in the brain, not on blood flow. That makes it a very different drug from Viagra, which works on blood vessels. The FDA label is candid that exactly how it improves desire in women is unknown. The MC1R activity explains why it can darken skin.
The RECONNECT trials enrolled 1,267 premenopausal women with HSDD across two 24-week studies. Women used it as needed, most often two or three times a month.
On a desire score that runs from 1.2 to 6, bremelanotide improved scores by about 0.5 to 0.6 points versus about 0.2 on placebo. On a distress scale, it cut distress by about 0.7 points versus 0.4 on placebo. Both results were statistically significant. About 25% of women on the drug had a meaningful jump in desire, compared to 17% on placebo.
The number of satisfying sexual events did not change versus placebo. And dropout was high, around 40% on drug in one study. An open-label extension reported the benefit held up over a year, but it had no control group.
In men, small studies found it produced erections, including in some men who did not respond to Viagra. It never went through approval for men.
Online, men and women use gray-market PT-141 for libido and men use it for erectile dysfunction. These uses are outside the label and have not been tested in proper trials.
Nausea is the big one. About 40% of women in the trials had it, mostly after the first dose, and it caused 8% to quit. Flushing affected about 20% and headache about 11%.
It briefly raises blood pressure, by up to about 6 points systolic, and lowers heart rate, usually back to normal within 12 hours. It should not be used by people with uncontrolled high blood pressure or known heart disease.
It can darken skin on the face, gums and breasts. That was rare at the approved frequency but common with daily dosing in studies, more likely in darker skin, and did not always fade after stopping. It can also lower blood levels of oral naltrexone, a medicine used for alcohol and opioid dependence.
From the label, not a recommendation. Vyleesi is 1.75 mg injected under the skin at least 45 minutes before sex, no more than once in 24 hours, and no more than eight doses a month. Community reports describe roughly 0.5 to 2 mg from gray-market vials, often starting low to limit nausea. Higher doses increase nausea, blood pressure effects and pigmentation. We do not give mixing or injection steps.
Vyleesi is an FDA-approved prescription drug, for premenopausal women with HSDD only. The label says it is not for men or postmenopausal women and not for enhancing sexual performance.
Gray-market PT-141 is a different story. The FDA named PT-141 in its August 24, 2026 warning letters to peptide sellers, calling those products unapproved new drugs and rejecting their “research use only” labels. We explain what those letters mean in our FDA warning letters post.
Compounding rules for a peptide that is the active ingredient of an approved drug are technical, and we have seen conflicting claims online. Ask the pharmacy for documentation if this applies to you. Athletes should check the current WADA list, since we could not confirm its status.
Is PT-141 the same as Vyleesi? It is the same molecule. Vyleesi is the FDA-approved, quality-controlled product. Gray-market vials are not.
Is it “female Viagra”? No. It acts on the brain’s desire pathways, not on blood flow, and the benefit is modest.
Does it work for men? Small studies were positive, but it is not approved for men.
How fast does it work? The label says to take it at least 45 minutes before. How long it lasts is unknown.
Why does it cause nausea? Nausea is the most common side effect, at about 40%, and is worst after the first dose.
Can it darken skin? Yes, especially with frequent use and darker skin, and it is not always reversible.
Who should avoid it? People with uncontrolled high blood pressure or heart disease, and people taking oral naltrexone.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.